[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621359":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":105,"collaborators":10,"id":108,"slug":109,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":10,"eligibilityCriteria":114,"healthyVolunteers":110,"sex":115,"minAge":116,"maxAge":10,"enrollmentInfo":117,"targetDuration":10,"studyType":120,"phases":10,"briefSummary":121,"conditions":122,"keywords":124,"overallStatus":45,"whyStopped":10,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"University of Malaya","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Normal dose group",null,"Patients receiving standard dose of chemotherapy",[13,14],"Other: Progression free survival","Other: Overall survival",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose reduction group","Patients receiving lower doses of chemotherapy",[13,14],[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"Progression free survival","PFS",[16,9],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Overall survival","OS",[16,9],[29],{"name":30,"affiliation":31,"role":32},"Mau Ern Poh, MBBS","Universiti Malaya","PRINCIPAL_INVESTIGATOR",[34,38],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},"CONTACT","+60379494422","ernestpoh@um.edu.my",{"name":39,"role":35,"phone":40,"phoneExt":10,"email":41},"Danouska Bala Krishnan","+603-79492351","danouska@ummc.edu.my",[43,61,78,93],{"facility":44,"status":45,"city":46,"state":10,"zip":10,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Queen Mary Hospital, The University of Hong Kong","RECRUITING","Hong Kong","HK",{"type":49,"coordinates":50},"Point",[51,52],114.17469,22.27832,{"lat":52,"lon":51},[55,59],{"name":56,"role":35,"phone":57,"phoneExt":10,"email":58},"Wang Chun Kwok","+85222556208","kwokwch@hku.hk",{"name":60,"role":32,"phone":10,"phoneExt":10,"email":10},"Chun Kwok Wang",{"facility":62,"status":45,"city":63,"state":64,"zip":10,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Hospital Tengku Ampuan Afzan","Kuantan","Pahang","Malaysia","MY",{"type":49,"coordinates":68},[69,70],103.326,3.8077,{"lat":70,"lon":69},[73,77],{"name":74,"role":35,"phone":75,"phoneExt":10,"email":76},"Sin Nee Tan","+6095572222","christine0507@live.com",{"name":74,"role":32,"phone":10,"phoneExt":10,"email":10},{"facility":79,"status":45,"city":80,"state":81,"zip":10,"country":65,"countryCode":66,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Hospital Wanita dan Kanak-Kanak Sabah","Kota Kinabalu","Sabah",{"type":49,"coordinates":83},[84,85],116.0724,5.9749,{"lat":85,"lon":84},[88,92],{"name":89,"role":35,"phone":90,"phoneExt":10,"email":91},"Seng Wee Cheo","+6088522600","cheosengwee@gmail.com",{"name":89,"role":32,"phone":10,"phoneExt":10,"email":10},{"facility":94,"status":45,"city":95,"state":10,"zip":10,"country":65,"countryCode":66,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"Universiti Malaya Medical Centre","Kuala Lumpur",{"type":49,"coordinates":97},[98,99],101.68653,3.1412,{"lat":99,"lon":98},[102,103],{"name":30,"role":35,"phone":36,"phoneExt":10,"email":37},{"name":104,"role":32,"phone":10,"phoneExt":10,"email":10},"Mau Ern Poh",{"type":32,"investigatorFullName":106,"investigatorTitle":107,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Poh Mau Ern","Professor Dr","100621359","impact-of-chemotherapy-dose-reductions-on-survival-outcomes-among-older-nsclc-patients-without-actionable-mutations-100621359",false,"NCT07369596","Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations","Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations: A Retrospective Cohort Study.","Inclusion Criteria:\n\n* Age ≥65 years\n* Histologically confirmed stage IV NSCLC\n* Negative for EGFR mutation, ALK rearrangement, and ROS1 fusion\n* Treated with at least ONE cycle of first-line chemotherapy\n\nExclusion Criteria:\n\n* Patients who received targeted therapy or immunotherapy as monotherapy in the first-line setting\n* Incomplete survival data","ALL","65 Years",{"count":118,"type":119},150,"ESTIMATED","OBSERVATIONAL","Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity.\n\nThis study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.",[123],"Non Small Cell Lung Carcinoma NSCLC",[125,126,127],"NSCLC","older patients","chemotherapy","2026-05-30",{"date":130,"type":131},"2026-06-02","ACTUAL",{"date":133,"type":131},"2026-01-01",{"date":135,"type":119},"2026-12-31",{"name":5,"class":6},4]